Welcome to the geko website

geko™ device

2018 marks the launch of our new website. We hope you like the fresh new look and improved navigation. The site places our clinical partners centre stage, and shines a light on their compelling research and readiness to embrace innovation to establish new therapies that address significant unmet need.

VTE prevention

NICE Guidance

Providing venous thromboembolism (VTE)
prophylaxis to all at risk hospital patients

NICE guidance (MTG19) supports the geko™ device to reduce thromboembolism risk for patients when other mechanical and pharmacological methods of prophylaxis are impractical or contraindicated1.

The NICE costing statement estimates a saving of £197* per patient when the geko™ device is used for a period of 6 days, when compared to no VTE prophylaxis and that under these circumstances use of the device will be cost saving until day 142.

The savings results from a reduction in the relative risk of DVT and the associated conditions of VTE such as post thrombotic syndrome as well as reduced length of hospital stay.

In high-risk patients when a combination of pharmacological and mechanical VTE prophylaxis is desirable but current mechanical prophylaxis is contraindicated or impractical, the geko™ device in combination with pharmacological prophylaxis will be cost neutral for up to 3 days compared to pharmacological prophylaxis alone2.

*In 2014 NICE estimated a cost saving of £197 up to 6 days of geko™ use.  The current saving, using an updated version of the same cost consequence model, is now £337 per patient3.

Reducing VTE risk in acute stroke patients

Through an audit of clinical practice, Firstkind has partnered with a major NHS Trust to assess use of the geko™ device for VTE prophylaxis in the acute stroke pathway.

Current practice is based on the CLOT-3* study, which reports that 31% of acute stroke patients are contraindicated or become intolerant to IPC, and carry a 6.3% risk of developing a symptomatic DVT4 – which suggests a significant level of unmet need.

The audit revealed that 36% of patients were contraindicated or became intolerant to IPC. It was to this unmet need cohort that the trust evaluated use of the geko™ device.

The results show that the geko TM is as effective as IPC at reducing DVT. The geko™ was well tolerated and offered an alternative prophylaxis strategy to IPC, ensuring all patients received VTE prophylaxis, where previously no prophylaxis could be given4.

References:

  1. NICE Guidance (MTG19). The geko™ device for reducing the risk of venous thromboembolism. Issued: June 2014.
  2. Costing statement: Implementing the NICE guidance on the geko™ device for reducing the risk of venous thromboembolism (MTG19). Issues June 2014.
  3. Health economic analysis on file Firstkind Ltd. 2018.
  4. J. Williams1, C. Roffe1, I. Natarajan1, C. Moss1, C. Lambert1, L. Richards2. The use of the geko™ device and the activation of the foot and calf pumps for prevention of venous thromboembolism in patients with acute stroke. 1. University Hospital of North Midland NHS Trust, Acute Stroke Unit, Stoke on Trent, United Kingdom. 2. Undergraduate School of Medicine- Keele University, Stoke on Trent, United Kingdom.

OnPulse Technology

The revolutionary neuromuscular electrostimulation technology developed by Firstkind

Find out more

OnPulse Technology

Hospital Applications device

Find out more

Partner with us

What can the geko™ do for my patients?

News

The geko™ device makes breakthrough in
pre-operative oedema reduction

News

Sky Medical Technology & the South Tees Hospitals NHS Foundation trust win prestigious Bionow award

News

The geko™ device receives FDA 510(k) clearance to market in the USA for prevention of venous thrombosis (DVT)